{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T16:57:34Z","timestamp":1772384254408,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver diseases. In most cases, NAFLD progresses from benign steatosis to steatohepatitis (NASH), and then to cirrhosis. No treatment is currently approved for NAFLD\/NASH in the clinic. Fenofibrate (FENO) has been clinically used to treat dyslipidemia for more than a half century, but its effects on NASH are not established. FENO\u2019s half-life is quite different between rodent and human. The aim of this study was to investigate the potential of pharmacokinetic-based FENO regime for NASH treatment and the underlying mechanisms.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Two typical mouse NASH models, methionine-choline deficient (MCD) diet-fed mice and choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-fed mice, were used. MCD model was designed as therapeutic evaluation in experiment 1 and CDAHFD model was designed as preventive in experiment 2. Three doses of FENO (5, 25, 125\u00a0mg\/kg), two times a day (BID), were administered to the above models. Serum markers of liver injury, cholestasis, and the histology of liver tissues were investigated. Normal mice were used as a model in experiment 3 for toxicity evaluation, Quantitative-PCR and Western Blot assays were used to investigate the inflammatory responses, bile acid synthesis as well as lipid catabolism.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Mice on the MCD and CDAHFD diets developed steatohepatitis as expected. Treatment with FENO (25\u00a0mg\/kg\u00b7BID) significantly decreased hepatic steatosis, inflammation and fibrosis in both therapeutic and preventive models. In the MCD model, the therapeutic action of FENO (25\u00a0mg\/kg\u00b7BID) and 125\u00a0mg\/kg\u00b7BID on histopathology and the expression of inflammatory cytokines were comparable. In reducing macrophage infiltration and bile acid load, FENO (25\u00a0mg\/kg\u00b7BID) was superior to 125\u00a0mg\/kg\u00b7BID. In all the aspects mentioned above, FENO (25\u00a0mg\/kg\u00b7BID) was the best among the 3 doses in the CDAHFD model. In a third experiment, the effects of FENO (25\u00a0mg\/kg\u00b7BID) and 125\u00a0mg\/kg\u00b7BID on lipid catabolism were comparable, but 125\u00a0mg\/kg\u00b7BID increased the expression of inflammatory factors and bile acid load. In both models, FENO (5\u00a0mg\/kg\u00b7BID) showed little effect in hepatic steatosis and inflammation, neither the adverse effects. FENO (125\u00a0mg\/kg\u00b7BID) aggravated liver inflammation, increased bile acid synthesis, and promoted the potential of liver proliferation. In toxicity risk assay, FENO (25\u00a0mg\/kg\u00b7BID) treatment showed low potential to trigger bile acid synthesis, inflammation and hepatocyte proliferation.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> A new regime, FENO (25\u00a0mg\/kg\u00b7BID) is potentially a therapeutic strategy for the NASH treatment. Translational medicine is warranted to prove its effectiveness in the clinic.<\/jats:p>","DOI":"10.3389\/fphar.2023.1190458","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:44:16Z","timestamp":1683870256000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design"],"prefix":"10.3389","volume":"14","author":[{"given":"Xinxue","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenzhe","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low hdl cholesterol levels: A multicenter, placebo-controlled, double-blind, randomized trial","volume":"25","author":"Arai","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13073-022-01081-3","article-title":"Single-cell multimodal analysis identifies common regulatory programs in synovial fibroblasts of rheumatoid arthritis patients and modeled TNF-driven arthritis","volume":"14","author":"Armaka","year":"2022","journal-title":"Genome Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"25168","DOI":"10.1074\/jbc.M110.123992","article-title":"Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice","volume":"285","author":"Bijland","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/hep.23049","article-title":"Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner","volume":"50","author":"Chanda","year":"2009","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s43440-019-00043-8","article-title":"Therapeutic action against chronic cholestatic liver injury by low-dose fenofibrate involves anti-chemotaxis via JNK-AP1-CCL2\/CXCL2 signaling","volume":"72","author":"Dai","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1111\/bph.13928","article-title":"Inhibition of JNK signalling mediates PPAR\u03b1-dependent protection against intrahepatic cholestasis by fenofibrate","volume":"174","author":"Dai","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1182\/blood-2013-02-486217","article-title":"Mast cell and macrophage chemokines CXCL1\/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation","volume":"121","author":"De Filippo","year":"2013","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1530\/joe-20-0018","article-title":"SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD","volume":"245","author":"Deng","year":"2020","journal-title":"J. Endocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/cphy.c120026","article-title":"Kupffer cells in the liver","volume":"3","author":"Dixon","year":"2013","journal-title":"Compr. Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12072-015-9633-1","article-title":"Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease","volume":"9","author":"El-Haggar","year":"2015","journal-title":"Hepatol. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/hep.26155","article-title":"Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come","volume":"57","author":"Ghonem","year":"2013","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.vph.2015.06.014","article-title":"Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome","volume":"74","author":"Gomaraschi","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.atherosclerosis.2015.07.038","article-title":"Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A field substudy","volume":"242","author":"Harmer","year":"2015","journal-title":"Atherosclerosis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jat.1516","article-title":"Dichloroacetate- and trichloroacetate-induced oxidative stress in the hepatic tissues of mice after long-term exposure","volume":"30","author":"Hassoun","year":"2010","journal-title":"J. Appl. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/imm.12219","article-title":"Distinct cytokines balance the development of regulatory T cells and interleukin-10-producing regulatory B cells","volume":"141","author":"Holan","year":"2014","journal-title":"Immunology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ejphar.2012.10.012","article-title":"Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy","volume":"698","author":"Kadian","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/jci6223","article-title":"Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting","volume":"103","author":"Kersten","year":"1999","journal-title":"J. Clin. Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e87179","DOI":"10.1371\/journal.pone.0087179","article-title":"Uridine prevents fenofibrate-induced fatty liver","volume":"9","author":"Le","year":"2014","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1084\/jem.161.3.475","article-title":"Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4\/80","volume":"161","author":"Lee","year":"1985","journal-title":"J. Exp. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages(\u2606)","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"B27","first-page":"541","article-title":"Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia","volume":"41","author":"Li","year":"2009","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban."},{"key":"B28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/00498254.2018.1438685","article-title":"Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism","volume":"49","author":"Li","year":"2019","journal-title":"Xenobiotica"},{"key":"B29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"B30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5551\/jat.35626","article-title":"Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: Results of the EFECTL study","volume":"24","author":"Oikawa","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study","volume":"12","author":"Oscarsson","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00018-005-5406-7","article-title":"Lipid-lowering drugs","volume":"63","author":"Pahan","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00109-005-0678-9","article-title":"Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand?","volume":"83","author":"Peters","year":"2005","journal-title":"J. Mol. Med. Berl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.bjp.0706917","article-title":"Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: A biochemical, histological and electrophysiological study","volume":"149","author":"Pierno","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1089\/jir.2014.0096","article-title":"Interferon-\u03b2 mediates signaling pathways uniquely regulated in hepatic stellate cells and attenuates the progression of hepatic fibrosis in a dietary mouse model","volume":"35","author":"Shimozono","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.3390\/ijms15057711","article-title":"Importance of Kupffer cells in the development of acute liver injuries in mice","volume":"15","author":"Tsutsui","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1194\/jlr.M070631","article-title":"Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase","volume":"58","author":"van der Veen","year":"2017","journal-title":"J. Lipid Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1006\/bbrc.2001.6319","article-title":"Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor alpha agonists","volume":"290","author":"Yamazaki","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e99245","DOI":"10.1371\/journal.pone.0099245","article-title":"Peroxisome proliferator-activated receptor \u03b1 activation induces hepatic steatosis, suggesting an adverse effect","volume":"9","author":"Yan","year":"2014","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"154798","DOI":"10.1016\/j.metabol.2021.154798","article-title":"Fenofibrate, a PPAR\u03b1 agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy","volume":"120","author":"Yoo","year":"2021","journal-title":"Metabolism"},{"key":"B43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fphar.2015.00238","article-title":"Nuciferine downregulates Per-Arnt-Sim kinase expression during its alleviation of lipogenesis and inflammation on oleic acid-induced hepatic steatosis in HepG2 cells","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1038\/onc.2016.367","article-title":"CXCL2\/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.bbrc.2018.04.157","article-title":"FGF21 mediates the protective effect of fenofibrate against acetaminophen -induced hepatotoxicity via activating autophagy in mice","volume":"503","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1190458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:44:20Z","timestamp":1683870260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1190458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":47,"alternative-id":["10.3389\/fphar.2023.1190458"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1190458","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"article-number":"1190458"}}